Antihypertensive drug use and the risk of prostate cancer (Canada)

Cancer Causes and Control

Volumn 15, Issue 6, 2004, Pages 535-541

  Perron, Linda ^a   Bairati, Isabelle ^a   Harel, François ^a   Meyer, François ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Centre de Recherche en Cancerologie   (Canada)

Author keywords

Antihypertensive agents; case control studies; databases; dose response relationship; prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; METHYLDOPA; MINOXIDIL; PRAZOSIN; RESERPINE; TERAZOSIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ARTICLE; CANADA; CANCER RISK; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG EXPOSURE; HUMAN; HYPERTENSION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RISK FACTOR; SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CANADA; CASE-CONTROL STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 4043163432     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CACO.0000036152.58271.5e     Document Type: Article

References (33)

1. Boyle P, Severi G (1999) Epidemiology of prostate cancer chemoprevention. Eur Urol 35: 370-376.
2. Brawley OW, Barnes S (2001) The epidemiology of prostate cancer in the United States. Semin Oncol Nurs 17: 72-77.
3. Brawley OW, Barnes S, Parnes H (2001) The future of prostate cancer prevention. Ann NY Acad Sci 952: 145-152.
4. Institut national du cancer du Canada (2002) Statistiques canadiennes sur le cancer 2002.
5. Grossman E, Messerli FH, Goldbourt U (2002) Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep 4: 195-201.
6. Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48: 999-1009.
7. World Health Organization (2001) Anatomical therapeutic classification (ATC) index including defined daily doses (DDD) for plain substances.
8. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106: 409-415.
9. Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169-170.
10. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219-225.
11. Benning CM, Kyprianou N (2002) Quinazoline-derived alpha1- adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res 62: 597-602.
12. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60: 4550-4555.
13. Kyprianou N, Chon J, Benning CM (2000) Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 9: 42-46.
14. Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N (2001) Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48: 71-78.
15. Valeri A, Azzouzi R, Drelon E, et al. (2000) Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 45: 66-71.
16. Kelloff GJ, Lieberman R, Steele VE, et al. (2001) Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57: 46-51.
17. Grossman E, Messerli FH, Boyko V, Goldbourt U (2002) Is there an association between hypertension and cancer mortality? Am J Med 112: 479-486.
18. Stumpe KO (2002) Hypertension and the risk of cancer: is there new evidence? J Hypertens 20: 565-567.
19. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11: 534-542.
20. Friedman GD (1997) Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 7: 486-489.
21. Cerhan JR, Pavuk M, Wallace RB (1999) Positive association between resting pulse and cancer incidence in current and former smokers. Ann Epidemiol 9: 34-44.
22. Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989) A prospective analysis of physical activity and cancer. Am J Epidemiol 130: 522-529.
23. Sorensen HT, Olsen JH, Mellemkjaer L, et al. (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 89: 165-170.
24. Friis S, Sorensen HT, Mellemkjaer L, et al. (2001) Angiotensin- converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92: 2462-2470.
25. Hole DJ, Hawthorne VM, Isles CG, et al. (1993) Incidence of and mortality from cancer in hypertensive patients. BMJ 306: 609-611.
26. Pahor M, Guralnik JM, Ferrucci L, et al. (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348: 493-497.
27. Jick H (1997) Calcium-channel blockers and risk of cancer. Lancet 349: 1699-700.
28. Olsen JH, Sorensen HT, Friis S, et al. (1997) Cancer risk in users of calcium channel blockers. Hypertension 29: 1091-1094.
29. Lever AF, Hole DJ, Gillis CR, et al. (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184.
30. Rosenberg L, Rao RS, Palmer JR, et al. (1998) Calcium channel blockers and the risk of cancer. JAMA 279: 1000-1004.
31. Lindholm LH, Anderson H, Ekbom T, et al. (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358: 539-544.
32. Vezina RM, Lesko SM, Rosenberg L, Shapiro S (1998) Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 11: 1420-1425.
33. Gann PH, Daviglus ML, Dyer AR, Stamler J (1995) Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 4: 611-616.